For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | 2024-12-31 | ||
|---|---|---|---|---|
| Research and development (including related party amounts of 915 and 891, respectively) | 59,129 | 44,350 | ||
| General and administrative (including related party amounts of 528 and 537, respectively) | 20,338 | 18,033 | ||
| Total operating expenses | 79,467 | 62,383 | ||
| Loss from operations | -79,467 | -62,383 | ||
| Interest income | 9,675 | 12,795 | ||
| Net loss | -69,792 | -49,588 | ||
| Basic EPS | -1.22 | -0.88 | ||
| Diluted EPS | -1.22 | -0.88 | ||
| Basic Average Shares | 57,330,192 | 56,587,142 | ||
| Diluted Average Shares | 57,330,192 | 56,587,142 | ||
Design Therapeutics, Inc. (DSGN)
Design Therapeutics, Inc. (DSGN)